Strategic priority (SP) 1. COMMUNICATION AND VISIBILITY
Strategic priority (SP) 2. COORDINATION AND SYNERGIES
Strategic priority (SP) 3. TRAINING AND DEVELOPMENT
Strategic priority (SP) 4. RESEARCH AND INNOVATION
Strategic priority (SP) 1. COMMUNICATION AND VISIBILITY
Strategic goal (SG) 1.1: Disseminate scientific evidence on pharmacokinetics and pharmacogenetics
Operational goal (OG) 1.1.1: Maintain and update the workgroup’s website.
OG 1.1.2: Optimize the workgroup’s performance on twitter: create new lists, update the accounts we follow, etc.)
OG 1.1.3: Bring out a quarterly newsletter with reports on clinical cases.
OG 1.1.4: Participate in SEFH’s national congress through workshops and/or a pre-congress course.
OG 1.1.5: Put together a volume with already-published newsletters (10-12 newsletters). ISBN.
OG 1.1.6: Create a whatsapp group for adherents and publicize its existence.
SG 1.2: Provide SEFH members with information on the clinical pharmacokinetics and pharmacogenetics units implemented in Spain..
OG 1.2.1: Define the criteria to be used to accredit pharmacokinetics and pharmacogenetics units.
OG 1.2.2: Update the PK and PG units map. Launch a 2nd survey in 2024.
SP 2. COORDINATION AND SYNERGIES
SG 2.1. Develop all the activities needed for proper coordination of the workgroup
OG 2.1.1: Organize the workgroup’s meetings.
OG 2.1.2: Prepare the workgroup’s annual report.
OG 2.1.3: Define the tasks to be performed by the workgroup’s trainee and by the workgroup’s resident.
OG 2.1.4: Maintain the workgroup’s drive and keep it up-to-date.
SG 2.2. Establish partnerships with other workgroups
OG 2.2.2: Organize seminars, workshops or pre-congress courses in collaboration with other workgroups.
SP 3. TRAINING AND DEVELOPMENT
SG 3.1. To lead and participate in educational initiatives and participate in them
OG 3.1.1. Produce an updated version of the resident’s handbook
OG 3.1.2. Keep up the workgroup’s existing partnership with the Miguel Hernandez University with respect to the Master’s course on pharmacokinetics.
SG 4.1. Pharmacokinetics program
OG 4.1.1. Follow up on the development of the WinPKS software. Status and expected progress.
SG 4.2. Lead and participate in research initiatives.
OG 4.2.1: Search for genetic markers in the treatment of idiomatic pulmonary fibrosis with pirfenidone and nintedanib project.
OG 4.1.2: Promote development of PhD dissertations on pharmacokinetics and pharmacogenetics.
(Fecha de actualización: 3 de octubre de 2022)